SCHEMBL21348773

SCHEMBL21348773

Cc1cccc(NC(=O)c2nnc(C)o2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 8/20 0.56
▸ MEN1 O00255 7/20 0.56
▸ RXFP1 Q9HBX9 1/20 0.56
▸ SMN1; SMN2 Q16637 8/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ KCNH2 Q12809 2/20 0.53
▸ KCNK3 O14649 2/20 0.53
▸ KCNK9 Q9NPC2 2/20 0.53
▸ RAB9A P51151 5/20 0.52
▸ NPC1 O15118 4/20 0.52
▸ TP53 P04637 3/20 0.52
▸ NFKB1 P19838 1/20 0.52
▸ NFKB2 Q00653 1/20 0.52
▸ RELA Q04206 1/20 0.52
▸ MAPT P10636 3/20 0.52
▸ LMNA P02545 2/20 0.52
▸ PKM P14618 2/20 0.52
▸ TSHR P16473 1/20 0.52
▸ ALDH1A1 P00352 3/20 0.51
▸ HTT P42858 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18415349 0.84 MEN1 (0.51) KMT2AMEN1SMN1; SMN2HSD17B10RAB9A
SCHEMBL21348780 0.83 ALDH1A1 (0.57) KMT2AMEN1SMN1; SMN2RAB9ANPC1
SCHEMBL21695763 0.83 FADS1 (0.52) KMT2AMEN1RXFP1SMN1; SMN2HSD17B10
SCHEMBL4788254 0.80 DGAT1 (0.62) KMT2AMEN1RXFP1SMN1; SMN2KCNK3
SCHEMBL21695764 0.79 CBLB (0.42) KMT2AMEN1SMN1; SMN2RAB9ANPC1
SCHEMBL2908619 0.74 MEN1 (0.89) KMT2AMEN1RXFP1SMN1; SMN2HSD17B10
SCHEMBL12745859 0.74 POLB (0.47) KMT2AMEN1SMN1; SMN2KCNH2KCNK3
SCHEMBL4253897 0.73 KCNK3 (0.93) KMT2AMEN1RXFP1KCNH2KCNK3
SCHEMBL5300455 0.72 DGAT1 (0.58) RAB9ANPC1
SCHEMBL10192041 0.72 SMN1; SMN2 (0.76) KMT2AMEN1RXFP1SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10556898-B2 Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease LYCERA CORPORATION (US) 2020-02-11 — — US disclosed
US-20190276447-A1 INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE LYCERA CORPORATION 2019-09-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190276447-A1 INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE ROCK1, ROCK2, TNK2 KMT2A 1854/4885MEN1 3494/4885RXFP1 434/4885
US-10556898-B2 Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease ROCK1, ROCK2, TNK2 KMT2A 1854/4885MEN1 3494/4885RXFP1 434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback